NCT00116610

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

A Phase II Study of Picoplatin as Second-Line Therapy for Subjects With Resistant or Refractory Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (planned)
• Sponsor: Poniard Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase II research study that is designed for patients who have small cell lung cancer (SCLC) that is no longer responding to treatment. Patients will receive picoplatin, a new platinum-based agent that is currently under investigation, in 21-day cycles.

Detailed description

Platinum drugs work by binding to DNA and preventing the rapid cell division of tumors. However, many tumors demonstrate a resistance to platinum drugs. Results from preclinical studies indicate that picoplatin (previously called AMD473 or ZD0473) may be able to overcome or partially overcome platinum resistance. More than 500 patients have received picoplatin in previous Phase I or Phase II clinical trials.

Conditions

• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	picoplatin

Timeline

• Start date: 2005-06-01
• Primary completion: 2007-03-01
• Completion: 2008-03-01
• First posted: 2005-06-30
• Last updated: 2009-01-21

Locations

55 sites across 3 countries: United States, Canada, Russia